Literature DB >> 25494844

Identifying aggressive forms of endometrioid-type endometrial cancer: new insights into molecular subtyping.

Yuexin Liu1, Russell R Broaddus, Wei Zhang.   

Abstract

Clinical heterogeneity represents a great challenge for cancer therapeutics. Molecular classification of patients into different subtypes based on genetic or epigenetic characteristics has the potential to revolutionize the clinical care and mechanistic understanding of a wide spectrum of cancers, including endometrial carcinoma, the most common gynecological cancer affecting women.

Entities:  

Keywords:  CTNNB1 mutation; cancer therapeutics; endometrial carcinoma; molecular subtyping; wnt signaling pathway

Mesh：

Substances：

Year:  2014        PMID： 25494844      PMCID： PMC4638381          DOI： 10.1586/14737140.2015.992420

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN： 1473-7140            Impact factor:   4.512


  18 in total

1.  Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer.

Authors:  Da Yang; Sofia Khan; Yan Sun; Kenneth Hess; Ilya Shmulevich; Anil K Sood; Wei Zhang
Journal:  JAMA       Date:  2011-10-12       Impact factor: 56.272

2.  Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism.

Authors:  Chunming Liu; Yiming Li; Mikhail Semenov; Chun Han; Gyeong Hun Baeg; Yi Tan; Zhuohua Zhang; Xinhua Lin; Xi He
Journal:  Cell       Date:  2002-03-22       Impact factor: 41.582

Review 3.  The different roles of ER subtypes in cancer biology and therapy.

Authors:  Christoforos Thomas; Jan-Åke Gustafsson
Journal:  Nat Rev Cancer       Date:  2011-07-22       Impact factor: 60.716

Review 4.  Molecular pathology of endometrial carcinoma.

Authors:  Xavier Matias-Guiu; Jaime Prat
Journal:  Histopathology       Date:  2013-01       Impact factor: 5.087

5.  Cancer statistics, 2013.

Authors:  Rebecca Siegel; Deepa Naishadham; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2013-01-17       Impact factor: 508.702

6.  Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation.

Authors:  H B Salvesen; S L Carter; M Mannelqvist; A Dutt; G Getz; I M Stefansson; M B Raeder; M L Sos; I B Engelsen; J Trovik; E Wik; H Greulich; T H Bø; I Jonassen; R K Thomas; T Zander; L A Garraway; A M Oyan; W R Sellers; K H Kalland; M Meyerson; L A Akslen; R Beroukhim
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-04       Impact factor: 11.205

7.  Comprehensive molecular portraits of human breast tumours.

Authors: 
Journal:  Nature       Date:  2012-09-23       Impact factor: 49.962

8.  IDH1 and IDH2 mutations in gliomas.

Authors:  Hai Yan; D Williams Parsons; Genglin Jin; Roger McLendon; B Ahmed Rasheed; Weishi Yuan; Ivan Kos; Ines Batinic-Haberle; Siân Jones; Gregory J Riggins; Henry Friedman; Allan Friedman; David Reardon; James Herndon; Kenneth W Kinzler; Victor E Velculescu; Bert Vogelstein; Darell D Bigner
Journal:  N Engl J Med       Date:  2009-02-19       Impact factor: 176.079

9.  Integrated genomic characterization of endometrial carcinoma.

Authors:  Cyriac Kandoth; Nikolaus Schultz; Andrew D Cherniack; Rehan Akbani; Yuexin Liu; Hui Shen; A Gordon Robertson; Itai Pashtan; Ronglai Shen; Christopher C Benz; Christina Yau; Peter W Laird; Li Ding; Wei Zhang; Gordon B Mills; Raju Kucherlapati; Elaine R Mardis; Douglas A Levine
Journal:  Nature       Date:  2013-05-02       Impact factor: 49.962

10.  TCGA divides gastric cancer into four molecular subtypes: implications for individualized therapeutics.

Authors:  Wei Zhang
Journal:  Chin J Cancer       Date:  2014-09-16
View more
  7 in total

1.  Lean Body Weight and Metformin Are Insufficient to Prevent Endometrial Hyperplasia in Mice Harboring Inactivating Mutations in PTEN.

Authors:  David A Iglesias; Qian Zhang; Joseph Celestino; Charlotte C Sun; Melinda S Yates; Rosemarie E Schmandt; Karen H Lu
Journal:  Oncology       Date:  2016-12-09       Impact factor: 2.935

2.  Molecular Evaluation of Low-grade Low-stage Endometrial Cancer With and Without Recurrence.

Authors:  Cathleen E Matrai; Kentaro Ohara; Kenneth Wha Eng; Shannon M Glynn; Pooja Chandra; Sudeshna Chatterjee-Paer; Samaneh Motanagh; Susanna Mirabelli; Boaz Kurtis; Bing He; Alexandros Sigaras; Divya Gupta; Eloise Chapman-Davis; Kevin Holcomb; Andrea Sboner; Olivier Elemento; Lora Hedrick Ellenson; Juan Miguel Mosquera
Journal:  Int J Gynecol Pathol       Date:  2021-09-06       Impact factor: 3.326

3.  The most important questions in cancer research and clinical oncology-Question 2-5. Obesity-related cancers: more questions than answers.

Authors:  Ajit Venniyoor
Journal:  Chin J Cancer       Date:  2017-01-31

4.  A global immune gene expression signature for human cancers.

Authors:  Yuexin Liu
Journal:  Oncotarget       Date:  2019-03-08

5.  Comparative transcriptome analysis between patient and endometrial cancer cell lines to determine common signaling pathways and markers linked to cancer progression.

Authors:  Madelaine J Cho-Clark; Gauthaman Sukumar; Newton Medeiros Vidal; Sorana Raiciulescu; Mario G Oyola; Cara Olsen; Leonardo Mariño-Ramírez; Clifton L Dalgard; T John Wu
Journal:  Oncotarget       Date:  2021-12-21

6.  Oncogenic signaling pathway dysregulation landscape reveals the role of pathways at multiple omics levels in pan-cancer.

Authors:  Na Wang; Dan-Ni He; Zhe-Yu Wu; Xu Zhu; Xiao-Ling Wen; Xu-Hua Li; Yu Guo; Hong-Jiu Wang; Zhen-Zhen Wang
Journal:  Front Genet       Date:  2022-08-17       Impact factor: 4.772

7.  Prognostic molecular biomarkers in endometrial cancer: A review.

Authors:  J Edgardo Hernández; Ailyn González-Montiel; Jesús C Ceb Allos-Villalva; David Cantú; Salim Barquet; Anny Olivares-Mundo; Luis A Herrera; Diddier Prada
Journal:  J Cancer Res Ther (Manch)       Date:  2019-12-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.